Nektar Therap

Forecast & Rating12 analysts currently cover Nektar Therap, with about 83.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $141.40, about 251.2% upside from the current price of $40.26. Price targets range from $50.00 to $192.00 — a wide spread, showing clear disagreement over just how much Nektar Therap can rise. Historically, about 34.1% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Nektar Therap closely still see room for the stock to rise. Data as of Oct 5, 2026; for reference only and not investment advice.